Retromer deficiency and Alzheimer's disease pathology
Retromer deficiency and Alzheimer's disease pathology
批准号:
9486649
负责人:
WEN-CHENG XIONG
金额:
$13.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2017-10-31
关键词:
AddressAgeAge-YearsAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAmino AcidsAmyloid beta-ProteinAmyloid beta-Protein PrecursorAutopsyBrainCell physiologyChronicCognitive deficitsDefectDementiaDendritesDendritic SpinesDepositionDiseaseEncephalitisEndosomesExhibitsFamilyFunctional disorderGenesGlutamatesGoalsGolgi ApparatusHeterozygoteHippocampus (Brain)HypersensitivityImpairmentInflammationInflammatoryLate Onset Alzheimer DiseaseLearningLoxP-flanked alleleMediatingMembrane ProteinsMemoryMicroRNAsMicrogliaMorphologyMusMutateMutationNerve DegenerationNeurodegenerative DisordersNeuronal DysfunctionNeuronsParkinson DiseasePathogenesisPathologicPathologyPatientsPeptidesPhenotypePresenile Alzheimer DementiaProteinsPublicationsResearchResistanceRetrievalRisk FactorsSignal TransductionSliceSwellingSynapsesTNF geneTNFSF11 geneTestingTg2576Vacuolar Protein Sortingaxonal degenerationbeta-site APP cleaving enzyme 1clinical investigationcytokinegamma secretasehippocampal pyramidal neuroninterestmorris water mazemutantneuropathologyneurotransmissionnovelnovel therapeutic interventionpreventpublic health relevanceselective expressionsmall hairpin RNAtraffickingtreatment strategyyoung adult
中文摘要
描述(由申请人提供):VPS 35是retromer的主要组分,对于膜蛋白的选择性内体-高尔基体修复至关重要。Vps 35/retromer功能障碍与阿尔茨海默病(AD)以及帕金森病(PD)的发病机制有关,因为Vps 35和SorLA(retromer的货物)基因的突变已分别在晚发性PD和AD患者中被鉴定。因此,研究VPS 35/retromer缺陷如何促进神经变性是相当有趣的。 本提案将检验三个假设。第一个假设是VPS 35/retromer在锥体神经元中的表达对于预防AD相关的神经病理学至关重要。第二个假设是VPS 35/retromer缺陷神经元在BACE 1逆行运输中受损,从而增加BACE 1活性并促进树突和轴突变性。第三个假设是VPS 35/retromer缺陷的小胶质细胞对TNF家族细胞因子高度敏感,释放过量的促炎细胞因子,促进脑炎症和神经变性。这两种假设都得到了我们的出版物和最近的初步研究的支持。我们希望这些研究不仅能建立VPS 35/retromer在预防BACE 1和小胶质细胞过度激活方面的新细胞功能,而且还能为神经退行性疾病(如AD和PD)的发病机制提供新的线索。我们也希望这项研究可以为治疗这些疾病提供新的治疗策略。
英文摘要
DESCRIPTION (provided by applicant): VPS35 is a major component of retromer that is essential for selective endosome-to-Golgi retrieval of membrane proteins. Dysfunction of VPS35/retromer is implicated in the pathogenesis of Alzheimer's disease (AD) as well as Parkinson's disease (PD), because mutations in Vps35 and SorLA (a cargo of retromer) genes have been identified in the late-onset PD and AD patients, respectively. Thus, it is of considerable interest to investigate how VPS35/retromer deficiency contributes to neurodegeneration. Three hypotheses will be tested in this proposal. The first hypothesis is that VPS35/retromer expression in pyramidal neurons is critical to prevent AD-relevant neuropathology. The second hypothesis is that VPS35/retromer deficient neurons are impaired in BACE1 retrograde trafficking, thus increasing BACE1 activity and promoting dendritic and axonal degeneration. The third hypothesis is that VPS35/retromer deficient microglial cells are hypersensitive to TNF� family cytokines, releasing excessive proinflammatory cytokines and promoting brain inflammation and neurodegeneration. Both hypotheses are supported by our publications and recent preliminary studies. We hope that the proposed studies will not only establish novel cellular functions of VPS35/retromer in preventing hyper-activation of BACE1 and microglia, but also shed new lights into pathogenesis of neurodegenerative disorders, such as AD and PD. We also hope that this research may point to new therapeutic strategies for the treatment of these disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development
-
批准号:10254624
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:WEN-CHENG XIONG
-
依托单位:
Skeletal Muscular Swedish Mutant APP in Alzheimer's Disease Development
-
批准号:10513298
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2021
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:9605932
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2017
-
负责人:WEN-CHENG XIONG
-
依托单位:
APP as a common denominator for Alzheimer's disease and osteoporosis
-
批准号:9903240
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2016
-
负责人:WEN-CHENG XIONG
-
依托单位:
APP as a common denominator for Alzheimer's disease and osteoporosis
-
批准号:9607371
-
项目类别:
-
资助金额:$28.61万
-
财政年份:2016
-
负责人:WEN-CHENG XIONG
-
依托单位:
APP as a common denominator for Alzheimer's disease and osteoporosis
-
批准号:9323223
-
项目类别:
-
资助金额:$9.39万
-
财政年份:2016
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:9059562
-
项目类别:
-
资助金额:$31.16万
-
财政年份:2014
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:8708256
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2014
-
负责人:WEN-CHENG XIONG
-
依托单位:
Retromer deficiency and Alzheimer's disease pathology
-
批准号:8842912
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2014
-
负责人:WEN-CHENG XIONG
-
依托单位:
Mechanisms of neuromuscular junction formation
-
批准号:10267688
-
项目类别:
-
资助金额:$56.87万
-
财政年份:2013
-
负责人:WEN-CHENG XIONG
-
依托单位:
Mechanisms of neuromuscular junction formation
-
批准号:10434135
-
项目类别:
-
资助金额:$56.41万
-
财政年份:2013
-
负责人:WEN-CHENG XIONG
-
依托单位:
Amyloid-RAGE Signaling in Bone Remodeling
-
批准号:8139580
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
APPswe as a risk factor for osteoporosis
-
批准号:9139032
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
Amyloid-RAGE Signaling in Bone Remodeling
-
批准号:8597386
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
Amyloid-RAGE Signaling in Bone Remodeling
-
批准号:8244935
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
APPswe as a risk factor for osteoporosis
-
批准号:10224044
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2011
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:7559625
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:8215796
-
项目类别:
-
资助金额:$31.51万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:7473548
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
Molecular Mechanisms Underlying Axon Pathfinding
-
批准号:7761689
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2008
-
负责人:WEN-CHENG XIONG
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: